Skip to main content
HCPCS Q5135 · Level II · Part B drug

Q5135: tocilizumab-aazg (Tyenne), HCPCS Level II drug code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for Q5135

Billing unit
1 MG
Inj, tyenne, 1 mg
ASP payment limit
$4.37
October 2026; +7.7% vs July 2026
Practitioner MUE
1200
MAI 3
OPPS status
SI G
APC 0784
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS Q5135 is the Level II code for Injection, tocilizumab-aazg (tyenne), biosimilar, 1 mg, billed per 1 MG. The Medicare Part B ASP payment limit for October 2026 is $4.37 per billing unit, up 7.7% from July 2026. The practitioner MUE allows up to 1200 units per date of service (MAI 3), so a full 1200-unit day is $5,244.00 at the current limit. Under OPPS it carries status indicator G in APC 0784. As a biosimilar it has its own code and ASP; the reference product cannot be billed under this code, and the JZ or JW modifier rules for discarded amounts apply per single-dose vial. With a 1 mg billing unit, a single administration can be hundreds of units; the unit count on the claim must equal the milligrams given, and rounding rules for partial units follow the contractor's guidance. Other HCPCS codes whose descriptor names tocilizumab: Q5133 (biosimilar tocilizumab-bavi (Tofidence) from Organon LLC); Q5156 (biosimilar tocilizumab-anoh (Avtozma) from Celltrion USA, Inc); Q0249 (for hospitalized adults and pediatric patients 2 years and older with COVID-19; non-biosimilar tocilizumab); Q0238 (for hospitalized adults with COVID-19); Q0237 (for hospitalized adults with COVID-19; tocilizumab-anoh); Q0234 (for hospitalized adults with COVID-19; tocilizumab-bavi). The ASP crosswalk maps 5 NDCs to it, sold as Tyenne by FreseniUS Kabi USA, LLC. No current Billing and Coding Article lists Q5135, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for Q5135 at $4.37 per 1 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $4.056 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for Q5135
QuarterPayment limitPerCoinsurance
October 2026$4.371 MG20%
July 2026$4.0561 MG—
CMS note: 8% of reference add-on applied

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 5 NDCs from 1 labeler to Q5135. Report the NDC in the claim's drug segment and bill the number of Q5135 units that equals the quantity administered divided by 1 MG; the last column gives units per full package.

NDCs that crosswalk to Q5135
NDCDrug nameLabelerPackage sizeBilling units / package
65219-0584-01TyenneFreseniUS Kabi USA, LLC0.9 × 1162
65219-0586-04TyenneFreseniUS Kabi USA, LLC0.9 × 1162
65219-0590-04TyenneFreseniUS Kabi USA, LLC4 × 180
65219-0592-10TyenneFreseniUS Kabi USA, LLC10 × 1200
65219-0594-20TyenneFreseniUS Kabi USA, LLC20 × 1400

Medically Unlikely Edits (MUE)

CMS publishes 3 MUE values for Q5135. For practitioners the limit is 1200 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for Q5135 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services12003 Date of Service Edit: ClinicalPrescribing Information
Facility outpatient hospital12003 Date of Service Edit: ClinicalPrescribing Information
DME supplier12003 Date of Service Edit: ClinicalPrescribing Information

MUE for Q5135 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists Q5135 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check Q5135 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

Q5135 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists Q5135 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, Q5135 carries status indicator G and is assigned to APC 0784, with a published national unadjusted payment of $4.37. Status G marks pass-through drug payment, which is time-limited.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), Q5135 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $4.37 per 1 MG, paid only when the drug is furnished integral to a covered surgical procedure.

Common denials for Q5135 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for Q5135

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS Q5135

What does HCPCS code Q5135 describe?

Q5135 is defined by CMS as "Injection, tocilizumab-aazg (tyenne), biosimilar, 1 mg". Each billing unit represents 1 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is Q5135 a CPT code?

No. Q5135 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as tocilizumab-aazg (Tyenne); CPT codes are five-character codes maintained by the AMA. On a Part B claim Q5135 reports the drug itself in 1 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for Q5135 in October 2026?

The ASP-based payment limit is $4.37 per 1 MG, with 20% beneficiary coinsurance. The July 2026 limit was $4.056. Commercial payers use their own fee schedules.

How many units of Q5135 can be billed per day?

The practitioner Medically Unlikely Edit is 1200 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Prescribing Information" as the rationale.

Which NDCs map to Q5135?

The October 2026 ASP crosswalk lists 5 NDCs from 1 labeler: Tyenne (FreseniUS Kabi USA, LLC). For example NDC 65219-0584-01 (package size 0.9) equals 162 billing units of Q5135.

Does Q5135 have NCCI bundling edits?

No active practitioner PTP pairs list Q5135 as a column-1 or column-2 code in the v323r0 release.

Q5135 vs Q5133: what is the difference?

Both are HCPCS Level II codes whose descriptor names tocilizumab. What sets Q5133 apart: biosimilar tocilizumab-bavi (Tofidence) from Organon LLC. Q5135 is billed per 1 mg, limit $4.37, MUE 1200; Q5133 is billed per 1 mg, limit $4.706, MUE 1200. Report the code whose descriptor matches the product and setting in the record.

Q5135 vs Q5156: what is the difference?

Both are HCPCS Level II codes whose descriptor names tocilizumab. What sets Q5156 apart: biosimilar tocilizumab-anoh (Avtozma) from Celltrion USA, Inc. Q5135 is billed per 1 mg, limit $4.37, MUE 1200; Q5156 is billed per 1 mg, limit $3.098. Report the code whose descriptor matches the product and setting in the record.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.